Trials / Completed
CompletedNCT04370808
VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection
VITACOV: Vitamin D-related Polymorphisms and Vitamin D Levels as Risk Biomarkers of COVID-19 Infection Severity
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 517 (actual)
- Sponsor
- University of Lisbon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Vitamin D deficiency has been linked to hypertension, autoimmune, infectious and cardiovascular diseases which are risk factors for COVID-19. Moreover, COVID-19 patients have a very high prevalence of hypovitaminosis D (Turin data). Taken together, we aim to investigate whether genetic variants in vitamin D-related genes contribute to a poor COVID-19 outcome, particularly in hypertension and CV patients, proposing thus a personalized therapeutics based on vitamin D supplementation in order to reduce the severity and deaths.
Detailed description
Collected data from Turin University indicate that hospitalized patients have a very high prevalence of hypovitaminosis D. Reports from China and Italy show that hypertension presents an increased risk of COVID-19-related death. Otherwise, observational studies suggest that 25(OH)D induces protection against respiratory pathogens while large-scale studies indicate that serum 25(OH)D-level is inversely correlated to hypertension prevalence. Recent published data (2020) shows that 66% of Portuguese adults present Vitamin D deficiency. HeartGenetics' genetic database with more than 8.500 Portuguese genotypes shows that the prevalence of vitamin D polymorphisms in this population is 4-fold higher than the EU average, increasing the risk of hypovitaminosis D.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Exposure | Individuals with SARS-CoV-2 exposure and COVID-19 symptoms. |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2021-01-01
- Completion
- 2021-01-31
- First posted
- 2020-05-01
- Last updated
- 2021-04-28
Locations
3 sites across 1 country: Portugal
Source: ClinicalTrials.gov record NCT04370808. Inclusion in this directory is not an endorsement.